Centre National De La Recherche Scientifique

Institut Gustave Roussy

Anne Chauchereau

Annick Harel-Bellan

Slimane Ait-Si-Ali

Florence Cabon-Georget

Francois Dautry

Catherine Gaudin

Jean Benard

Karim Fizazi

Nader Al Nakouzi

Luis Martinez

Nicolas Jean-Paul Martin

François Dautry

The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest.

Prostate cancer cell lines and their use in screening method

A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3' or 5&#x2032; ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.

SiRNA-based cancer treatment

A method of treating a disease resulting from the expression of a harmful gene is described. The method includes the step of administering a therapeutically effective amount of a pharmaceutical composition having at least one double stranded oligonucleotide including two complementary oligonucleotide sequences forming a hybrid. Each oligonucleotide sequence comprises at one of their 3' or 5&#x2032; ends one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid. One of the oligonucleotide sequences is substantially complementary to a target sequence belonging to a DNA or messenger RNA molecule of a gene coding a mutated or nonmutated androgen receptor.

Inhibitor oligonucleotides and their use for specific repression of a gene

Growing community of inventors

Fontenay-aux-Roses, France

Anne Chauchereau